Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: The inventors disclose nucleic acids of HIV-2 encoding the entire envelope glycoprotein and peptide regions thereof. Also described are purified and cloned nucleic acids having the entire HIV-2 genome. The nucleic acids can be used to produce polypeptides corresponding to the HIV-2 envelope gene or peptides from specific regions of the HIV-2 envelope gene. Uses in hybridization assays are also disclosed.

Abstract: A novel human retrovirus which is the aetiological agent of acquired immune deficiency syndrome (AIDS), designated lymphadenopathy-associated virus (LAV), was isolated from the lymph nodes of a patient suffering from generalized persistant lymphadenopathy. LAV displays a tropism for CD4.sup.+ lymphocytes, a Mg.sup.2+ -dependent reverse transcriptase (RT) activity, a density of 1.16-1.17 as determined by sucrose gradient centrifugation, a particle diameter of 139 nm, and a p25 antigen that is immunologically distinct from the HTLV-I/II p24 protein. Radioimmunoprecipitation analysis (RIPA) of .sup.35 S-cysteine-labeled viral or cellular lysates employing patient antisera resulted in the identification of a viral antigen having a molecular weight of 110 kDa. Endoglycosidase treatment of this antigen produces a protein with a molecular weight of 90 kDa. Methods are disclosed for the preparation of hybridomas producing LAV gp110-specific monoclonal antibodies (Mabs).

Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type 2 (HIV-2), samples of which have been deposited at CNCM and having Accession Numbers I-502 and I-532. The invention also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp36 and gp130-140 envelope glycoproteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. The invention further relates to polyclonal and monoclonal antibodies specific for the antigens of HIV-2, particularly antibodies specific for gp130-140 envelope glycoprotein. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp36 or gp130-140.

Abstract: A novel lentivirus, designated the human immunodeficiency virus type 2 (HIV-2.sub.ROD), was isolated from West African patients with acquired immune deficiency syndrome (AIDS). A recombinant lambda phage library was constructed from HIV-2.sub.ROD -infected CEM genomic DNA. Overlapping molecular clones were obtained and the nucleotide sequence of the complete 9.5-kilobase (kb) HIV-2.sub.ROD genome ascertained. The genetic organization of HIV-2 is analogous to that of other retroviruses and consists of the 5'LTR-gag-pol-central region-env-nef-3'LTR. The central region also encodes for the regulatory proteins Tat and Rev, as well as the ancillary proteins Vif, Vpr, and Vpx. The proteins encoded by this proviral clone will provide novel immunologic, biochemic, and diagnostic reagents useful for the detection of HIV-2.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are-capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: This invention is directed to an isolated antibody specific for gp110 glycoprotein of a human immunodeficiency virus type 1 (HIV-1), and a hybridoma which produces such an antibody. HIV-1 is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).

Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: The invention relates to a new variety of retroviruses designated Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hydridization probes, derived from the RNA of HIV-2.

Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.

Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.

Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.

Abstract: The invention relates to a new variety of retroviruses designated human immunodeficiency virus type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.